Clinical Trial: NCT04116437
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | BeiGene |
| Information Provided By: | BeOne Medicines |
| Last Update Posted: | 2026-01-28 |
Study Overview
Brief Summary
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.
Official Title
Conditions
Intervention / Treatment
- Drug: Zanubrutinib
Other Study ID Numbers
- BGB-3111-215
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | BeiGene |
| Information Provided By: | BeOne Medicines |
| Last Update Posted: | 2026-01-28 |
Study Overview
Brief Summary
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.
Official Title
Conditions
Intervention / Treatment
- Drug: Zanubrutinib
Other Study ID Numbers
- BGB-3111-215